Strategies to Extend Plasma Half-Lives of Recombinant Antibodies

Recombinant antibodies, including whole antibodies, antibody fragments, antibody fusion proteins or conjugates, and more recently also small antibody mimetics, have found increasing applications as therapeutics, e.g. for the treatment of cancer or inflammatory diseases. While whole antibodies have a...

Full description

Saved in:
Bibliographic Details
Published in:BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy biopharmaceuticals, and gene therapy, 2009-01, Vol.23 (2), p.93-109
Main Author: Kontermann, Roland E.
Format: Article
Language:English
Subjects:
Albumins - genetics
Animals
Antibodies
Antibodies - blood
Antibodies - chemistry
Antibodies - genetics
Antibodies, Monoclonal - blood
Antibodies, Monoclonal - chemistry
Antibodies, Monoclonal - genetics
Area Under Curve
Bacterial Proteins - genetics
Biomedical and Life Sciences
Biomedicine
Cancer Research
Drug Carriers
Drug Development
Drugs
Half-Life
Health aspects
Humans
Immunoglobulin Fc Fragments - blood
Immunoglobulin Fc Fragments - chemistry
Immunoglobulin Fc Fragments - genetics
Immunoglobulin G - blood
Immunoglobulin G - chemistry
Immunoglobulin G - genetics
Management
Molecular Medicine
Molecular Mimicry
Monoclonal antibodies
Pharmacotherapy
Polyethylene Glycols - chemistry
Product/Service Evaluations
Receptors, Fc - physiology
Recombinant Fusion Proteins - blood
Recombinant Fusion Proteins - chemistry
Recombinant Fusion Proteins - genetics
Recombinant Proteins - blood
Recombinant Proteins - chemistry
Recombinant Proteins - genetics
Therapeutics, Experimental
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recombinant antibodies, including whole antibodies, antibody fragments, antibody fusion proteins or conjugates, and more recently also small antibody mimetics, have found increasing applications as therapeutics, e.g. for the treatment of cancer or inflammatory diseases. While whole antibodies have an exceptionally long half-life, small antibody derivatives often suffer from rapid elimination from the circulation. In order to improve administration and therapeutic efficacy, modifications to extend the plasma half-life have been developed and implemented in these antibody formats. This review provides a comprehensive summary of the various strategies currently available to extend plasma half-lives of recombinant antibodies.
ISSN:1173-8804
1179-190X
DOI:10.2165/00063030-200923020-00003